CD274 and cancer: To date, the FDA has approved six drugs (pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and cemiplimab) that target the PD-1/PD-L1 pathway for cancer immunotherapy, and many studies are currently underway to obtain additional approvals (7).